Published July 30, 2020
Buffalo Business First reports on the progress of two UB-affiliated companies. UB spinoff POP Biotechnologies has announced a $3 million investment and formation of a joint venture with Eubiologics for the development of an RSV vaccine and other vaccine candidates. Jonathan Lovell, associate professor of biomedical engineering, is co-founder of the company.
Additionally, Garwood Medical Devices, a UB partner company, was named as one of the top 10 medical device companies to watch in 2020 by Qualio, a software provider for medical device and pharmaceutical companies. Garwood's products include a method of controlling biofilm infections on implants, based on work done in the labs of UB engineering and medical researcher Mark Ehrensberger and UB medical researcher Anthony Campagnari, a SUNY Distinguished Professor. Garwood has space in UB buildings and has also leveraged various UB resources, including UB’s Buffalo Institute for Genomics and Data Analytics (BIG).